JP2017523985A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523985A5
JP2017523985A5 JP2017506294A JP2017506294A JP2017523985A5 JP 2017523985 A5 JP2017523985 A5 JP 2017523985A5 JP 2017506294 A JP2017506294 A JP 2017506294A JP 2017506294 A JP2017506294 A JP 2017506294A JP 2017523985 A5 JP2017523985 A5 JP 2017523985A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
polypeptide
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017506294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/068012 external-priority patent/WO2016020413A1/en
Publication of JP2017523985A publication Critical patent/JP2017523985A/ja
Publication of JP2017523985A5 publication Critical patent/JP2017523985A5/ja
Pending legal-status Critical Current

Links

JP2017506294A 2014-08-05 2015-08-05 抗原用担体分子 Pending JP2017523985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179945 2014-08-05
EP14179945.2 2014-08-05
PCT/EP2015/068012 WO2016020413A1 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Publications (2)

Publication Number Publication Date
JP2017523985A JP2017523985A (ja) 2017-08-24
JP2017523985A5 true JP2017523985A5 (enExample) 2018-07-19

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506294A Pending JP2017523985A (ja) 2014-08-05 2015-08-05 抗原用担体分子

Country Status (16)

Country Link
US (1) US10245310B2 (enExample)
EP (1) EP3177324A1 (enExample)
JP (1) JP2017523985A (enExample)
KR (1) KR20170039709A (enExample)
CN (1) CN108064174A (enExample)
AR (1) AR101455A1 (enExample)
AU (1) AU2015299008B2 (enExample)
BE (1) BE1022792B1 (enExample)
BR (1) BR112017002183A2 (enExample)
CA (1) CA2957118A1 (enExample)
EA (1) EA201790239A1 (enExample)
IL (1) IL250238A0 (enExample)
MX (1) MX2017001638A (enExample)
SG (1) SG11201700673RA (enExample)
WO (1) WO2016020413A1 (enExample)
ZA (1) ZA201700824B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000341A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
JP2020515629A (ja) * 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
JP7399934B2 (ja) * 2018-07-04 2023-12-18 バックスサイト・インコーポレイテッド 免疫原性複合体の改良
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
BR112021019826A2 (pt) * 2019-04-02 2021-12-07 Vaxcyte Inc Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230250142A1 (en) * 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
EP4165065A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Gbs ferritin nanoparticles
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
GB202215634D0 (en) * 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612679A1 (en) * 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1828231A2 (en) 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US20100150943A1 (en) * 2006-07-26 2010-06-17 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
AU2010204139A1 (en) * 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) * 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201114923D0 (en) * 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2014138418A (ru) * 2012-02-24 2016-04-10 Новартис Аг Белки пилей и композиции

Similar Documents

Publication Publication Date Title
JP2017523985A5 (enExample)
JP2013079285A5 (enExample)
JP2012501959A5 (enExample)
JP2016040284A5 (enExample)
JP2013503110A5 (enExample)
RU2017144606A (ru) Иммуноцитокины на основе il-15 и il-15rа домена sushi
JP2012126742A5 (enExample)
JP2015529678A5 (enExample)
JP2018015005A5 (enExample)
HRP20191852T1 (hr) Polipeptidi
JP2016527286A5 (enExample)
JP2016512425A5 (enExample)
JP2010500399A5 (enExample)
JP2016513638A5 (enExample)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2015501329A5 (enExample)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
JP2015518818A5 (enExample)
JP2010166916A5 (enExample)
JP2019506862A5 (enExample)
JP2015505309A5 (enExample)
JP2015509707A5 (enExample)
JP2013520487A5 (enExample)
BR112015009280A2 (pt) preparações liofilizadas de melfalana flufenamida
JP2013523718A5 (enExample)